



## Catapult Venture Managers Ltd has made an investment into Liverpool-based molecular diagnostics company Biofortuna Ltd

The funding, part of a £1m package, will be used to launch the company's first genotyping products and to allow it to continue development of its future product pipeline.

Biofortuna designs and develops innovative genotyping and antibody screening tests for the clinical healthcare market. Its initial products focus on assessing solid organ compatibility between an organ donor and a recipient, in order to reduce the probability of rejection. Future products will operate at higher resolutions and so have applications in bone marrow transplantation, blood banking and drug efficacy.

Catapult provides equity capital of between £200k and £2m  
for growing businesses

For further information please contact: Ben Bolt on  
0121 616 0180 or visit [www.catapult-vm.co.uk](http://www.catapult-vm.co.uk)

**East Midlands Office:** Malt House, 13 Narborough Wood Park,  
Desford Road, Enderby, Leicester, LE19 4XT. Tel: 0116 238 8200  
Email: [mail@catapult-vm.co.uk](mailto:mail@catapult-vm.co.uk)  
[www.catapult-vm.co.uk](http://www.catapult-vm.co.uk)

**West Midlands Office:** One Victoria Square,  
Birmingham, B1 1BD. Tel: 0121 616 0180  
Email: [mail@catapult-vm.co.uk](mailto:mail@catapult-vm.co.uk)  
[www.catapult-vm.co.uk](http://www.catapult-vm.co.uk)

Investors in our funds include:



Catapult Venture Managers Limited. Registered in England and Wales No: 03818199. Registered Office: Malt House, 13 Narborough Wood Business Park, Desford Road, Enderby, Leicester LE19 4XT. Tel: 0116 238 8200. Fax: 0116 239 6997. Catapult Venture Managers Limited is authorised and regulated by the Financial Services Authority.